Cumberland Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Cumberland Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.19M	Sell	9,376 -231	-2%	-$108K	0.32%	55
2025 Q4	$4.36M	Sell	9,607 -137	-1%	-$59.1K	0.27%	77
2025 Q3	$3.82M	Sell	9,744 -36,826	-79%	-$15.4M	0.25%	74
2025 Q2	$20.7M	Sell	46,570 -177	-0.4%	-$81.6K	1.44%	22
2025 Q1	$22.7M	Sell	46,747 -579	-1%	-$270K	1.75%	20
2024 Q4	$19.1M	Buy	47,326 +4,126	+10%	+$1.91M	1.33%	22
2024 Q3	$20.1M	Buy	43,200 +14,541	+51%	+$6.98M	1.39%	23
2024 Q2	$13.4M	Sell	28,659 -728	-2%	-$316K	0.98%	27
2024 Q1	$12.3M	Buy	+29,387	New	+$12.4M	0.89%	30
2021 Q1	–	Sell	-115	Closed	-$27K	–	197
2020 Q4	$27K	Buy	+115	New	+$26.4K	﹤0.01%	165

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cumberland Partners's VRTX Position: Q1 2026 in Review

Cumberland Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q1 2026, selling an estimated $108K and leaving 9,376 shares worth $4.19M. The position accounts for 0.32% of the portfolio, ranked #55.

Cumberland Partners first reported a position in VRTX in Q4 2020 and has held it in 10 quarters since. The position peaked at $22.7M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Cumberland Partners held 9,376 shares of Vertex Pharmaceuticals worth $4.19M as of Q1 2026.
Cumberland Partners sold 231 Vertex Pharmaceuticals shares in Q1 2026, an estimated $108K.
Vertex Pharmaceuticals made up 0.32% of Cumberland Partners's portfolio in Q1 2026, its #55 holding.
Cumberland Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 10 quarters since.
Cumberland Partners's Vertex Pharmaceuticals position peaked at $22.7M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Cumberland Partners's 13F filing for Q1 2026, filed 14 May 2026.